8-K: Agenus Secures $10M Note from Zydus, Pledges MiNK Shares

Agenus Inc. entered into a Promissory Note Agreement for up to $10 million with Zydus Pharmaceuticals, collateralized by MiNK Therapeutics shares, to fund Q4 2025 operations.

Summary

• Agenus Inc. entered into a Promissory Note Agreement (the Note) with Zydus Pharmaceuticals (USA) Inc. for up to $10,000,000 on October 8, 2025.
• The Note bears interest at 3.81% per annum.
• It matures upon the closing of the Asset Purchase Agreement and Securities Purchase Agreement (APA/SPA) signed by Agenus and Zydus on June 3, 2025, or within 10 days if the APA/SPA closings will not be consummated.
• Proceeds from the Note will fund operational expenses of the Emeryville and Berkeley facilities for the fourth quarter of 2025 and make certain payments owed in respect of assets subject to the APA.
• The amount used for Q4 2025 operational expenses will be forgiven and not repaid if the APA/SPA closes.
• Agenus pledged 822,910 shares of common stock of MiNK Therapeutics, Inc. (NASDAQ: INKT) as collateral for the Note.
• A control agreement related to these shares provides Zydus certain rights in the event of a default under the Note.
• The pledge is expected to be released upon satisfaction of the obligations under the Note (including repayment or forgiveness in connection with an APA/SPA closing).

Sentiment

Score: 6

Explanation: While securing $10M in funding is positive for short-term liquidity, the need for bridge financing and pledging significant collateral (MiNK shares) suggests ongoing financial management challenges. The forgiveness feature tied to the APA/SPA closing is a positive contingency, mitigating some risk.

Positives

• Secured up to $10,000,000 in bridge financing to cover operational expenses for Q4 2025 and make payments related to the pending APA.
• A significant portion of the loan (funding Q4 2025 operational expenses) will be forgiven if the APA/SPA closes, reducing future debt obligations.
• The funding helps ensure continued operations at key facilities (Emeryville and Berkeley) during a transitional period.

Negatives

• Agenus pledged 822,910 shares of MiNK Therapeutics, Inc. common stock as collateral, tying up a valuable asset.
• The Note bears interest at 3.81% per annum, adding to financing costs.
• The need for this bridge financing suggests potential liquidity management challenges ahead of the APA/SPA closing.
• Default under the Note would grant Zydus certain rights over the pledged MiNK Therapeutics shares.

Risks

• If the APA/SPA does not close, Agenus will be required to repay the full $10,000,000 principal amount plus interest, and the forgiveness feature will not apply.
• Risk of default on the Promissory Note, which could lead to Zydus exercising its rights over the pledged 822,910 MiNK Therapeutics shares.
• Reliance on the successful and timely closing of the APA/SPA for debt forgiveness and overall financial stability.

Future Outlook

The Promissory Note is designed to provide bridge financing until the closing of the Asset Purchase Agreement and Securities Purchase Agreement (APA/SPA) signed on June 3, 2025. Proceeds will fund Q4 2025 operational expenses, with a forgiveness feature contingent on the APA/SPA closing. The pledge on MiNK Therapeutics shares is expected to be released upon satisfaction of the Note obligations.

Industry Context

Biotechnology and pharmaceutical companies frequently utilize various financing mechanisms, including promissory notes, to manage cash flow, fund ongoing operations, or bridge financing gaps, particularly in anticipation of larger strategic transactions like asset sales or mergers. This agreement aligns with industry practices for managing liquidity during M&A processes.

Stakeholder Impact

• Shareholders: The financing provides short-term liquidity but involves pledging a significant asset (MiNK shares). The outcome of the APA/SPA will heavily influence the financial impact, including potential debt forgiveness.
• Employees: The funding helps ensure continued operational stability at the Emeryville and Berkeley facilities for Q4 2025.
• Creditors (Zydus): Zydus gains a secured position over MiNK Therapeutics shares, reducing its risk exposure related to the Note.

Next Steps

• Closing of the Asset Purchase Agreement and Securities Purchase Agreement (APA/SPA) signed on June 3, 2025.
• Filing of the full text of the Promissory Note, related pledge agreement, and control agreement as exhibits to Agenus's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.
• Release of the pledge on MiNK Therapeutics shares upon satisfaction of the Note obligations (repayment or forgiveness).

Key Dates

Recommendation

The Promissory Note provides necessary bridge financing and includes a favorable forgiveness clause contingent on the APA/SPA closing, which is a positive for short-term liquidity. However, the need for this financing and the pledging of significant collateral (MiNK shares) highlight ongoing financial pressures. The overall investment thesis remains largely dependent on the successful completion of the APA/SPA, making a 'Hold' recommendation appropriate until further clarity on the larger transaction.

Keywords

Agenus, Zydus, Promissory Note, MiNK Therapeutics, Collateral, APA/SPA, Financing, Biotechnology, Pharmaceuticals, Debt